[ Full Table of Contents ] [ Printer Friendly Version in PDF Format ]
Date: November 2, 2005
To: Ms. Courtney M. Price, Vice President, CHEMSTAR, American Chemistry Council
Re: Naphthalene Information Quality Act Request for Reconsideration submitted February 18, 2005
Dear Ms. Price:
We are responding on behalf of the National Institute for Environmental Health Sciences to your February 18,2005 Request for Reconsideration (RFR) submitted on behalf of the Naphthalene Panel of the American Chemistry Council (ACC) . The RFR requests correction of information disseminated by the National Toxicology Program (NTP) concerning the Background Document for Naphthalene and the review of scientific data relevant to NTP's consideration of naphthalene for listing in the 11 th Report on Carcinogens (RoC).
In considering your request, we reviewed the NIH and HHS Information Quality Guidelines (http://aspe.hhs.gov/infoquality/Guidelines/NIHinfo2.shtml and http://aspe.hhs.gov/infoQuality/Guidelines/index.shtml), the RoC Listing Criteria, your April 1, 2004 Request for Correction of Information with all attachments, and the January 18,2005 response from the NTP. This information was used in determining the merits of your appeal.
Request for Correction of the Background Document
We concluded that there is no evidence
of noncompliance with the NIH and HHS Information Quality Guidelines with
respect to the NTP's handling of the Background
Document for Naphthalene. The reasons for this determination are as follows:
Request for Correction of the RGI and RG2 Summary Reports
With respect to the second request made
in your Request for Reconsideration regarding the summary reports from the
review groups (RG 1 and RG2)1, we conclude that these summaries
do, in fact, provide a concise assessment of the primary rationales for the
recommendations of the two groups. Specifically, the RG 1 report states, in
support of its vote of 6 yes to 1 no: "The committee felt that the NTP
two-year inhalation study in F344 rats provided strong evidence for the
carcinogenicity of naphthalene in that species... The committee agreed that
the evidence of carcinogenicity in B6C3F1 mice was less
impressive... There was some discussion as to whether the Listing Criteria of
increased tumor incidence 'to an unusual degree with regard to incidence, site
or type' applied to the NTP naphthalene rat study... Many felt that the
observed carcinogenic response in rats was sufficient to justify listing
naphthalene as reasonably anticipated to be a human carcinogen."
The synopsis of the discussion found in the RG2 summary report is similar in character: concise, but informative. The RG2 found itself split in its vote and was unable to make a majority recommendation for either listing or not listing naphthalene as reasonably anticipated to be a human carcinogen. The reasons for the split votes, as the summary makes clear, were due to differences in how the individuals on the committee interpreted the 2-year inhalation study results within the framework of the listing criteria (there was no disagreement concerning the actual study results). Specifically, as stated in the summary, members who voted against listing did so because they judged that "the results of the mouse study were not sufficient to say it is positive in this species and ... that the nasal tumors observed in the rat study, although rare, were insufficient to meet the criteria for listing in the RoC, without supporting evidence in mice." Members who voted for listing believed that "the results of the inhalation bioassay studies in rats and mice were sufficient." The section of the report covering the discussion of the animal data gives additional information about the study results and the lack of resolution within RG2 about whether the data constituted sufficient justification for listing naphthalene under the existing RoC Listing Criteria.
I would also like to let you know that the NTP is currently working to revise its process for review of future nominations to the RoC to address guidance provided by the Final Information Quality Bulletin for Peer Review from the Office of Management and Budget (70FR2664). The NTP provided an overview of a general process for peer review of NTP publications, including the RoCbackground documents and substance profiles, at the August 18 meeting of the NTP Board of Scientific Counselors.
Request for Correction of the RoC Subcommittee Proceedings
With respect to the third request made
in your Request for Reconsideration regarding the conduct of the RoC Subcommittee Meeting of November 19, 20021,
we conclude that it is an inappropriate request because procedures or
proceedings of meetings are not defined as "scientific information"
under the NIH or HHS Information Quality Guidelines and are therefore not
subject to request for correction under the Guidelines. It is our understanding,
from the discussion on Page 8 of the NTP's January
18, 2005 response to the initial request, that the events of the November
19,2002 RoC Subcommittee meeting have been raised and
responded to in other correspondence, and we will not address them here.
In conclusion, upon extensive review of the information provided, we find that with respect to the development and use of the Background Document on Naphthalene and the summaries of the RG 1 and RG2 scientific review group meetings on Naphthalene, the NTP is in compliance with the NIB and HHS Information Quality Guidelines.
The NTP is planning to revise the process for review for the RoC, as was mentioned at the August 18, 2005 meeting of their Board of Scientific Counselors. The NTP will certainly welcome receiving comments on any proposed changes in the review process.
We thank you for your interest and contribution to the RoC process; your input is vital for helping to make the RoC as accurate as possible in order to serve the best interests of public health.
Sincerely,
Sheila A. Newton, Ph.D. Director, Office of Science Policy and Planning,NIEHS
Note:
1.http://ntp.niehs.nih.gov/ntpweb/index.cfm?obiectid=BD126CBO-F1F6-975E-76939DCC0D9C5A9C#N.